Published in Immunopharmacology on July 12, 1994
Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature (2014) 2.26
Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology (2004) 1.96
Regulation of mast cell responses in health and disease. Crit Rev Immunol (2011) 1.50
Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med (2008) 1.40
G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2. Eur J Pharmacol (2011) 1.12
Impact of actin rearrangement and degranulation on the membrane structure of primary mast cells: a combined atomic force and laser scanning confocal microscopy investigation. Biophys J (2009) 1.03
PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Mol Pharmacol (2011) 1.00
Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies. J Gen Physiol (1998) 0.97
Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice. J Allergy Clin Immunol (2012) 0.97
Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett (2009) 0.91
Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.87
Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol (2012) 0.86
Applications of atomic force microscopy in biophysical chemistry of cells. J Phys Chem B (2010) 0.86
Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. Mucosal Immunol (2013) 0.83
Significance of Conversation between Mast Cells and Nerves. Allergy Asthma Clin Immunol (2005) 0.81
Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation. Anesthesiology (2013) 0.77
Mast cells: pivotal players in cardiovascular diseases. Curr Cardiol Rev (2008) 0.76
Novel phenotype in beagle dogs characterized by skin response to compound 48/80 focusing on skin mast cell degranulation. Exp Anim (2015) 0.75
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol (1976) 2.90
Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates. J Biol Chem (1972) 2.72
Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med (1981) 2.63
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem (1978) 2.32
G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci (1990) 2.32
Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08
Structure and function of the anaphylatoxins. Springer Semin Immunopathol (1984) 2.07
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
[Neuropeptides and inflammation: presumed mechanisms in neurogenic inflammation]. Pathol Biol (Paris) (1990) 1.98
The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene (2007) 1.97
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol (2000) 1.57
A modified method for chemotaxis under agarose. J Immunol Methods (1979) 1.55
ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer (2003) 1.53
Heat-induced fragmentation of human alpha 2-macroglobulin. J Biol Chem (1979) 1.53
The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol (1981) 1.51
ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res (2000) 1.51
Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol (1980) 1.48
Role of cell surface contact in the kinetics of superoxide production by granulocytes. J Clin Invest (1983) 1.48
Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol (1989) 1.44
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol (1983) 1.44
Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. J Biol Chem (2000) 1.42
Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol (1980) 1.41
Regulation of immune response by components of the complement cascade and their activated fragments. Springer Semin Immunopathol (1983) 1.41
Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett (1990) 1.37
Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by N-formyl-Met-Leu-Phe or complement component C5a is independent of phospholipase activation. Proc Natl Acad Sci U S A (1983) 1.37
C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med (1995) 1.36
Neutrophil chemotactic factors promote leukocytosis. A common mechanism for cellular recruitment from bone marrow. J Immunol (1992) 1.36
C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A (1979) 1.34
Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol (1994) 1.28
Limited degradation of the third component (C3) of human complement by human leukocyte elastase (HLE): partial characterization of C3 fragments. Biochemistry (1977) 1.26
Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest (1974) 1.25
Biochemistry and biology of anaphylatoxins. Complement (1986) 1.25
Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther (1989) 1.23
Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol (1985) 1.23
Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a. Proc Natl Acad Sci U S A (1981) 1.23
Can calmodulin inhibitors be used to probe calmodulin effects? Biochem Pharmacol (1981) 1.23
Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b. J Immunol (1983) 1.22
Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol (1993) 1.21
Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal Biochem (1984) 1.21
Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene. Biochim Biophys Acta (1985) 1.21
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest (1979) 1.20
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 1.18
Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization. J Biol Chem (1979) 1.17
Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res (2000) 1.16
C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol (1990) 1.16
Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc Natl Acad Sci U S A (1977) 1.16
C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol (1997) 1.15
Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Infect Immun (1996) 1.15
Airway epithelium releases a relaxant factor: demonstration with substance P. Eur J Pharmacol (1986) 1.15
Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med (1994) 1.14
Circular dichroism of C3a anaphylatoxin. Effects of pH, heat, guanidinium chloride, and mercaptoethanol on conformation and function. J Biol Chem (1975) 1.14
Arachidonic acid metabolites and airway epithelium-dependent relaxant factor. J Pharmacol Exp Ther (1987) 1.13
Microvascular effects of anaphylatoxins C3a and C5a. J Immunol (1985) 1.13
Anaphylactic actions of platelet-activating factor. Am J Pathol (1981) 1.12
Release of leukotrienes from guinea pig lung stimulated by C5ades Arg anaphylatoxin. J Immunol (1982) 1.10
Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol (1983) 1.10
Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. J Immunol (1981) 1.10
Natural polyamines stimulate G-proteins. Biochem J (1992) 1.10
Quantitative comparisons of neutrophil chemotaxis in four animal species. Clin Immunol Immunopathol (1980) 1.09
Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol (1996) 1.09
Potentiation by tumour necrosis factor-alpha of calcium signals induced by bradykinin and carbachol in human tracheal smooth muscle cells. Br J Pharmacol (1995) 1.08
Leukotriene C4 production by murine mast cells: evidence of a role for extracellular leukotriene A4. Proc Natl Acad Sci U S A (1985) 1.08
The extraction of leukotrienes (LTC4, LTD4, and LTE4) from tissue fluids: the metabolism of these mediators during IgE-dependent hypersensitivity reactions in lung. Anal Biochem (1983) 1.08
The active site of C3a anaphylatoxin. J Biol Chem (1980) 1.07
Inability of the C3a anaphylatoxin to promote cellular lysis. Nature (1980) 1.07
Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry (1989) 1.07
Sodium-potassium ATPase, calcium, and immunological histamine release. Biochem Pharmacol (1983) 1.07
Biologic activity of synthetic analogues of C5a anaphylatoxin. J Immunol (1992) 1.07
Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol (1999) 1.06
The pancreas as a source of cardiovascular cell activating factors. Microcirculation (2000) 1.06
Characterization of the human neutrophil response to sex pheromones from Streptococcus faecalis. Am J Pathol (1989) 1.05
Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide. J Biol Chem (1984) 1.05
Characterization of muscarinic receptors in human, guinea pig and rat lung. J Pharmacol Exp Ther (1989) 1.05
Interaction of substance P, compound 48/80 and mastoparan with the alpha-subunit C-terminus of G protein. Immunol Lett (1990) 1.04
A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol (1992) 1.04
Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol (1999) 1.03
C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology (2000) 1.03
Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol (1983) 1.02
The primary structure of porcine C3a anaphylatoxin. J Immunol (1976) 1.01
Complete primary structure of human C4a anaphylatoxin. J Biol Chem (1981) 1.01
Protein kinase C substrates from bovine brain. Purification and characterization of neuromodulin, a neuron-specific calmodulin-binding protein. J Biol Chem (1989) 1.01
Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J Immunol (1992) 1.01
Sodium-potassium ATPase inhibition potentiates compound 48/80-induced histamine secretion from mast cells. Br J Pharmacol (1984) 1.01